Compare Goldman Sachs Group Inc (GS) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goldman Sachs Group Inc vs Repligen Corporation Common Stock — how do they compare? Goldman Sachs Group Inc trades at $880.8 (market cap $255.86B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Goldman Sachs Group Inc is far larger — about 22.6× Repligen Corporation Common Stock's market cap, and Goldman Sachs Group Inc pays a 2.28% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Goldman Sachs Group Inc for 100 Days and Repligen Corporation Common Stock for 0 Days on average.
| GS | RGEN | |
|---|---|---|
Market Cap | $255.86B | $11.31B |
Volume | 3,405,238 | 1,216,919 |
Sector | Financials | Health |
52-Week High | $1.15K | $194.57 |
52-Week Low | $744.60 | $102.87 |
Typical Hold Time | 100 Days | 0 Days |
Enterprise Value | $255.77B | $11.20B |
Dividend Yield | 2.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Goldman Sachs (GS) trades at $891.91, down 0.23% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q3 2026) and improving profitability (net margin 31.68%, ROE 18.33%). Revenue growth accelerated to $58.28B in 2025 with guidance targeting $70B. Recent news highlights AI expansion and wealth management growth, though Q3 FICC business may soften.
GS presents a compelling value opportunity with attractive valuation (P/E 13.77) and 40% analyst buy ratings. Upside to $1,160 consensus target offers ~30% potential, supported by dividend growth and operational efficiency. Risks include market volatility, competitive pressures, and execution on AI/wealth management expansion. The balance sheet remains robust with $122B equity despite negative operating cash flows.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
